MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
Absorbed dose calculations provide a scientific basis for evaluating the biological effects associated with administered radiopharmaceuticals. In cancer therapy, radiation dosimetry also supports treatment planning, dose-response analyses, predictions of therapy effectiveness, and completeness of patient medical records. In this study, we evaluated the organ radiation absorbed doses resulting from intravenously administered 111In- and 90Y-Ibritumomab Tiuxetan (Zevalin). Methods: Ten patients (six male, four female) with non-Hodgkin’s lymphoma, cared for at three different medical centers, were administered tracer 111In-Ibritumomab Tiuxetan and were assessed using planar scintillation camera imaging at five time points, blood clearance measurements, and CT-organ volumetrics, to determine patient-specific organ biokinetics and dosimetry. Explicit attenuation correction based on transmission scan or transmission measurements provided the fraction of 111In administered activity in seven major organs, the whole body, and remainder tissues over time through complete decay. Activity-time curves were constructed, and radiation doses were calculated using MIRD methods and implementing software (OLINDA-EXM). Results: Mean radiation absorbed doses in 10 cancer patients for 111In- and for 90-Y-Ibritumomab Tiuxetan are reported for 24 organs and the whole body. Biological uptake and retention data are given for seven major source organs, remainder tissues, and the whole body. Median absorbed dose values calculated by this method were compared to previously published dosimetry for Zevalin and the product package insert. Conclusions: Careful dosimetry techniques provide useful information on absorbed dose from administered radiopharmaceuticals in patients. The importance of patient-specific dosimetry emerges in high-dose radioimmunotherapy when the objective of treatment planning is to achieve disease cures safely by limiting radiation doses to any critical normal organ to a maximum tolerable value.
- Research Organization:
- Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830
- OSTI ID:
- 958447
- Report Number(s):
- PNNL-SA-62232; JNMEAQ; 600306000; TRN: US1000381
- Journal Information:
- Journal of Nuclear Medicine, 50(4):644-652, Vol. 50, Issue 4; ISSN 0161-5505
- Country of Publication:
- United States
- Language:
- English
Similar Records
Logistics of therapy with the ibritumomab tiuxetan regimen
Relative Biologic Effects of Low-Dose-Rate {alpha}-Emitting {sup 227}Th-Rituximab and {beta}-Emitting {sup 90}Y-Tiuexetan-Ibritumomab Versus External Beam X-Radiation
Related Subjects
ATTENUATION
BIOLOGICAL EFFECTS
BLOOD
DECAY
DISEASES
DOSIMETRY
GAMMA CAMERAS
MEDICAL ESTABLISHMENTS
MEDICAL RECORDS
NEOPLASMS
ORGANS
PATIENTS
PLANNING
RADIATION DOSES
RADIATIONS
RADIOIMMUNOTHERAPY
RADIOPHARMACEUTICALS
RETENTION
THERAPY
Y-90-Ibritumomab Tiuxetan
Zevalin
In-111-Ibritumomab Tiuxetan
MIRD dose estimate report
lymphoma
dosimetry
antibody
radiopharmaceutical